Ex vivo exposure of bone marrow from chronic kidney disease donor rats to pravastatin limits renal damage in recipient rats with chronic kidney disease

Table 4 Terminal measurements of bone marrow cell recipients with post hoc P values

Week 12	Healthy + DMEM BMC recipients ( n = 5)	Healthy + pravastatin BMC recipients ( n = 5)	CKD + DMEM BMC recipients ( n = 10)	CKD + pravastatin BMC recipients ( n = 9)	CKD + DMEM BMC vs. healthy + DMEM BMC	CKD + DMEM BMC vs. CKD + pravastatin BMC
Body weight (g)	376 ± 23	379 ± 26	359 ± 38	373 ± 22	ns	ns
Heart weight (g/100 g BW)	0.44 ± 0.07	0.44 ± 0.03	0.47 ± 0.08	0.44 ± 0.05	ns	ns
Kidney weight (g/100 g BW)	0.59 ± 0.07	0.56 ± 0.05	0.53 ± 0.06	0.55 ± 0.04	0.063	ns
MAP (mmHg)	149 ± 28	146 ± 35	173 ± 21	153 ± 21	0.095	0.091
GFR (μl/minute/100 g)	371 ± 68	352 ± 119	237 ± 159	261 ± 149	0.057	ns
ERPF (μl/minute/100 g)	1538 ± 224	1388 ± 502	844 ± 626*	1157 ± 359	<0.05	ns
Hematocrit	0.45 ± 0.01	0.44 ± 0.01	0.42 ± 0.03*	0.46 ± 0.02^†	<0.05	<0.05
FF (%)	24.1 ± 2.4	26.2 ± 4.7	29.9 ± 4.5*	26.4 ± 3.7	<0.05	0.071

Data presented as mean ± standard deviation. BMC, bone marrow cell; BW, body weight; CKD, chronic kidney disease; DMEM, Dulbecco’s modified Eagle medium; ERPF, effective renal plasma flow; FF, filtration fraction; GFR, glomerular filtration rate; MAP, mean arterial pressure. *P <0.05 compared with healthy BMC recipients, ^† P <0.05 compared with CKD BMC recipients. Trends (P <0.1) are only indicated with the exact P value.